Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 457 | 67 | 382 |
| Samples | 229 | 42 | 183 |
| Peptides | 169 | 28 | 139 |
Function
KPNA2 · Karyopherin subunit alpha 2
The import of proteins into the nucleus is a process that involves at least 2 steps. The first is an energy-independent docking of the protein to the nuclear envelope and the second is an energy-dependent translocation through the nuclear pore complex. Imported proteins require a nuclear localization sequence (NLS) which generally consists of a short region of basic amino acids or 2 such regions spaced about 10 amino acids apart. Proteins involved in the first step of nuclear import have been identified in different systems. These include the Xenopus protein importin and its yeast homolog, SRP1 (a suppressor of certain temperature-sensitive mutations of RNA polymerase I in Saccharomyces cerevisiae), which bind to the NLS. KPNA2 protein interacts with the NLSs of DNA helicase Q1 and SV40 T antigen and may be involved in the nuclear transport of proteins. KPNA2 also may play a role in V(D)J recombination. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2016].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000330459 | P52292 | 240 | 168 |
| ENST00000537025 | P52292 | 216 | 161 |
| ENST00000676857 | A0A7I2V487* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 168 amino-acid changes on canonical ENST00000330459 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in KPNA2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in KPNA2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 2/42 5% | 9/612 1% |
| Burkitts Lymphoma | 0/32 0% | 3/196 2% |
| Melanoma | 3/210 1% | 24/1899 1% |
| Bladder Carcinoma | 2/58 3% | 11/956 1% |
| Squamous Cell Lung Carcinoma | 7/57 12% | 3/810 0% |
| Gastric Carcinoma | 4/74 5% | 16/1809 1% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Colorectal Carcinoma | 0/143 0% | 24/3239 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Head and Neck Carcinoma | 3/85 4% | 7/1574 0% |
| Other Solid Cancers | 0/94 0% | 9/1515 1% |
| Neuroendocrine Tumour | 3/154 2% | 1/577 0% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 7/1390 0% |
| Biliary Tract Carcinoma | 0/54 0% | 5/950 1% |
| Hepatocellular Carcinoma | 1/46 2% | 10/2210 0% |
| Pancreatic Carcinoma | 2/89 2% | 6/1611 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Breast Carcinoma | 6/144 4% | 7/3264 0% |
| Glioma | 0/52 0% | 8/2127 0% |
| Ovarian Carcinoma | 3/109 3% | 1/998 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 5/2550 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 4/2534 0% |
| Kidney Carcinoma | 0/85 0% | 3/1862 0% |
| Prostate Carcinoma | 0/13 0% | 3/2105 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
Mutation Distribution
Where KPNA2 is mutated · all tissues, split by cell line vs tissue
How many mutations in KPNA2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 457 mutations in KPNA2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|